Blocking PIGF, a future in anti-angiogenic therapy?;Les anticorps anti-PIGF: Un nouvel outil thérapeutique anti-angiogénique?

Medecine/Sciences

Volumn 24, Issue 5, 2008, Pages 459-462

  Galaup, Ariane ^a   Germain, Stéphane ^b,c,d  

^a FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^b Centre de Recherche Interdisciplinaire en Biologie   (France)

^c INSERM   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CXCL1 CHEMOKINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; GEMCITABINE; NEUROPILIN 1; PLACENTAL GROWTH FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; TYROSINE KINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANTIBODY; ENZYME INHIBITOR; METALLOPROTEINASE; PIGF PROTEIN, HUMAN; PROTEIN;

BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOGENESIS; CELL INFILTRATION; CELL MIGRATION; COLORECTAL CANCER; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; IC 50; INFLAMMATION; ISCHEMIA; LEUKOCYTE COUNT; LYMPHOMA; MEDICAL RESEARCH; METASTASIS; NOTE; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVASCULARIZATION; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; IMMUNOLOGY; NEOPLASM; PATHOPHYSIOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES; ENZYME INHIBITORS; HUMANS; INFLAMMATION; METALLOPROTEASES; NEOPLASMS; PROTEINS;

EID: 44949187510     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2008245459     Document Type: Note

References (18)

1. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007 ; 7 : 475-85.
2. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008 ; 358 : 95-7.
3. Fischer C, Jonckx B, Mazzone M, et al. Anti-PIGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007 ; 131 : 463-75.
4. Luttun, A, Tjwa M, Moons L, et al. 2002. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002 ; 8 : 831-40.
5. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001 ; 7 : 575-83.
6. Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy : continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005 ; 23 : 8136-9.
7. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006 ; 24 : 16-24.
8. Autiero M, Waltenberger J, Communi D, et al. Role of PIGF in the intra- and intermodular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003 ; 9 : 936-43.
9. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 2005 ; 65 : 550-63.
10. Kulke MH. Neuroendocrine tumours : clinical presentation and management of localized disease. Cancer Treat Rev 2003 ; 29 : 363-70.
11. Ratain MJ. Phase II oncology trials : let's be positive. Clin Cancer Res 2005 ; 11 : 5661-2.
12. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007 ; 6 : 734-45.
13. Behar-Cohen F, Sennlaub F, Berdugo M. Espoirs thérapeutiques dans la dégénérescence maculaire liée à l'âge. Med Sci (Paris) 2007 ; 23 : 127-9.
14. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002 ; 87 : 161-7.
15. Leighl NB, Paz-Ares L, Douillard JY, et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer : National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 2005 ; 23 : 2831-9.
16. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer : a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002 ; 20 : 4434-9.
17. Orlando L, Cardillo A, Rocca A, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 2006 ; 17 : 961-7.
18. Blay JY. Le futur des thérapeutiques ciblées en oncologie, trouver les cibles, traiter tôt et au long cours. Med Sci (Paris) 2008 ; 23 : 1073-4.